One Wealth Capital Management LLC Makes New $699,000 Investment in IDEXX Laboratories, Inc. $IDXX

One Wealth Capital Management LLC bought a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,339 shares of the company’s stock, valued at approximately $699,000.

Several other institutional investors have also recently made changes to their positions in the stock. Bank of New York Mellon Corp bought a new position in shares of IDEXX Laboratories in the second quarter worth $628,223,000. Arrowstreet Capital Limited Partnership grew its position in shares of IDEXX Laboratories by 52.4% in the first quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company’s stock valued at $471,335,000 after purchasing an additional 288,471 shares in the last quarter. Alyeska Investment Group L.P. raised its stake in shares of IDEXX Laboratories by 97.3% during the 2nd quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company’s stock valued at $211,146,000 after purchasing an additional 197,808 shares during the period. Montrusco Bolton Investments Inc. raised its stake in shares of IDEXX Laboratories by 93.4% during the 1st quarter. Montrusco Bolton Investments Inc. now owns 342,120 shares of the company’s stock valued at $186,707,000 after purchasing an additional 165,188 shares during the period. Finally, American Capital Management Inc. purchased a new stake in IDEXX Laboratories during the 2nd quarter worth about $85,341,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director Lawrence D. Kingsley sold 2,203 shares of the company’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $532.08, for a total value of $1,172,172.24. Following the transaction, the director directly owned 9,568 shares in the company, valued at $5,090,941.44. This represents a 18.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.79% of the stock is owned by corporate insiders.

IDEXX Laboratories Stock Down 1.1%

IDXX opened at $560.38 on Friday. The firm has a market capitalization of $44.15 billion, a P/E ratio of 39.41, a price-to-earnings-growth ratio of 2.99 and a beta of 1.55. IDEXX Laboratories, Inc. has a one year low of $500.61 and a one year high of $769.98. The company has a fifty day moving average price of $532.69 and a 200-day moving average price of $551.64. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. The company had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.20 billion. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%. The firm’s revenue was up 9.7% compared to the same quarter last year. During the same quarter last year, the business posted $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Equities research analysts expect that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IDXX has been the subject of several analyst reports. Barclays cut their target price on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Weiss Ratings raised IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. KeyCorp started coverage on IDEXX Laboratories in a research report on Monday, October 12th. They set a “sector weight” rating on the stock. UBS Group increased their price target on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a report on Wednesday, August 5th. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Seven research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $744.09.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology, and related products and services for the animal health and water testing markets. The company primarily serves veterinary practices, helping them diagnose and monitor diseases through laboratory tests, in-clinic analyzers, software, and digital practice-management solutions.

IDEXX’s companion animal offerings include hematology, chemistry, urinalysis, immunodiagnostics, and imaging-related products, along with reference laboratory services and veterinary software.